Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus

The development of biological therapies has had an impact on the management of several medical conditions. Their use in systemic lupus erythematosus (SLE), however, remains very limited. This review has summarized the evidence on the clinical effect of biologicals in SLE. Biological drugs with a num...

Full description

Bibliographic Details
Main Author: Rosalie Magro
Format: Article
Language:English
Published: SAGE Publishing 2019-09-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X19874309
id doaj-8e7a6e926314472ab1e74d9e5740f7f5
record_format Article
spelling doaj-8e7a6e926314472ab1e74d9e5740f7f52021-07-14T10:34:43ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182019-09-011110.1177/1759720X19874309Biological therapies and their clinical impact in the treatment of systemic lupus erythematosusRosalie MagroThe development of biological therapies has had an impact on the management of several medical conditions. Their use in systemic lupus erythematosus (SLE), however, remains very limited. This review has summarized the evidence on the clinical effect of biologicals in SLE. Biological drugs with a number of targets have been studied in several phase II and III randomized controlled trials (RCTs). Positive results have been obtained in phase III RCTs with belimumab and this led to its license for active SLE. The clinical experience with belimumab has confirmed the efficacy and safety of belimumab in SLE. Promising results have been noted in phase II trials for blisibimod, sifalimumab, anifrolumab, and ustekinumab. Despite the fact that the RCTs with rituximab did not achieve their primary endpoint, clinical experience with rituximab is extensive and shows favorable clinical response in refractory renal and non-renal SLE. It is hoped that further ongoing phase III RCTs on a number of biological agents in SLE will highlight the potential role of other biologicals in the management of this challenging and heterogeneous condition.https://doi.org/10.1177/1759720X19874309
collection DOAJ
language English
format Article
sources DOAJ
author Rosalie Magro
spellingShingle Rosalie Magro
Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
Therapeutic Advances in Musculoskeletal Disease
author_facet Rosalie Magro
author_sort Rosalie Magro
title Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
title_short Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
title_full Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
title_fullStr Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
title_full_unstemmed Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
title_sort biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
publisher SAGE Publishing
series Therapeutic Advances in Musculoskeletal Disease
issn 1759-7218
publishDate 2019-09-01
description The development of biological therapies has had an impact on the management of several medical conditions. Their use in systemic lupus erythematosus (SLE), however, remains very limited. This review has summarized the evidence on the clinical effect of biologicals in SLE. Biological drugs with a number of targets have been studied in several phase II and III randomized controlled trials (RCTs). Positive results have been obtained in phase III RCTs with belimumab and this led to its license for active SLE. The clinical experience with belimumab has confirmed the efficacy and safety of belimumab in SLE. Promising results have been noted in phase II trials for blisibimod, sifalimumab, anifrolumab, and ustekinumab. Despite the fact that the RCTs with rituximab did not achieve their primary endpoint, clinical experience with rituximab is extensive and shows favorable clinical response in refractory renal and non-renal SLE. It is hoped that further ongoing phase III RCTs on a number of biological agents in SLE will highlight the potential role of other biologicals in the management of this challenging and heterogeneous condition.
url https://doi.org/10.1177/1759720X19874309
work_keys_str_mv AT rosaliemagro biologicaltherapiesandtheirclinicalimpactinthetreatmentofsystemiclupuserythematosus
_version_ 1721303073947648000